Loading...
XTSXRX
Market cap93mUSD
Dec 24, Last price  
11.55CAD
1D
-0.86%
1Q
5.00%
Jan 2017
44.38%
Name

Biosyent Inc

Chart & Performance

D1W1MN
XTSX:RX chart
P/E
20.75
P/S
4.24
EPS
0.56
Div Yield, %
1.43%
Shrs. gr., 5y
-3.49%
Rev. gr., 5y
7.97%
Revenues
32m
+13.12%
711,035748,5201,514,4911,104,3251,101,9911,029,9021,681,2102,808,6665,024,1547,799,42612,211,12715,388,19617,922,27020,762,75521,527,02821,424,32422,332,16828,618,21827,925,18731,590,302
Net income
6m
+18.35%
-312,657505,257383,145-125,991-287,892-260,55752,160420,3921,541,3171,928,0283,154,0793,764,8894,309,5055,206,2775,705,3864,369,2953,795,3356,281,5665,458,3456,460,127
CFO
5m
+2.15%
-104,394747,809222,25814,249-260,094-342,79237,892596,0791,249,1452,118,9343,640,0132,810,9204,399,0226,546,1316,286,5984,771,0236,894,4254,674,8884,948,7565,054,974
Dividend
Sep 04, 20240.045 CAD/sh
Earnings
Mar 11, 2025

Profile

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
IPO date
May 22, 1981
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
31,590
13.12%
27,925
-2.42%
28,618
28.15%
Cost of revenue
23,354
20,567
19,913
Unusual Expense (Income)
NOPBT
8,236
7,358
8,705
NOPBT Margin
26.07%
26.35%
30.42%
Operating Taxes
2,074
1,972
2,097
Tax Rate
25.18%
26.81%
24.09%
NOPAT
6,162
5,386
6,608
Net income
6,460
18.35%
5,458
-13.11%
6,282
65.51%
Dividends
(1,913)
(484)
Dividend yield
1.70%
0.55%
Proceeds from repurchase of equity
(3,629)
(3,649)
(1,838)
BB yield
3.23%
4.16%
1.73%
Debt
Debt current
183
174
162
Long-term debt
2,259
2,616
2,952
Deferred revenue
(1,403)
Other long-term liabilities
1,403
Net debt
(26,245)
(26,164)
(25,281)
Cash flow
Cash from operating activities
5,055
4,949
4,675
CAPEX
(174)
(519)
(93)
Cash from investing activities
884
(10,790)
(4,837)
Cash from financing activities
(5,785)
(4,371)
(2,076)
FCF
4,852
4,634
4,946
Balance
Cash
26,187
28,696
28,212
Long term investments
2,500
258
183
Excess cash
27,107
27,558
26,964
Stockholders' equity
32,473
31,134
29,736
Invested Capital
8,873
6,882
6,049
ROIC
78.23%
83.30%
142.94%
ROCE
22.77%
21.25%
26.30%
EV
Common stock shares outstanding
12,170
12,541
12,871
Price
9.22
31.71%
7.00
-15.25%
8.26
4.42%
Market cap
112,211
27.83%
87,784
-17.43%
106,317
2.65%
EV
85,966
61,621
81,036
EBITDA
8,691
7,809
9,162
EV/EBITDA
9.89
7.89
8.84
Interest
68
77
85
Interest/NOPBT
0.83%
1.05%
0.98%